ATE429432T1 - Indazolderivate als faktor xa-inhibitoren - Google Patents
Indazolderivate als faktor xa-inhibitorenInfo
- Publication number
- ATE429432T1 ATE429432T1 AT04731155T AT04731155T ATE429432T1 AT E429432 T1 ATE429432 T1 AT E429432T1 AT 04731155 T AT04731155 T AT 04731155T AT 04731155 T AT04731155 T AT 04731155T AT E429432 T1 ATE429432 T1 AT E429432T1
- Authority
- AT
- Austria
- Prior art keywords
- factor
- compounds
- formulae
- chem
- factor viia
- Prior art date
Links
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical class C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 title 1
- 229940123583 Factor Xa inhibitor Drugs 0.000 title 1
- 108010054265 Factor VIIa Proteins 0.000 abstract 4
- 108010074860 Factor Xa Proteins 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 4
- 229940012414 factor viia Drugs 0.000 abstract 4
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 208000001435 Thromboembolism Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000002785 anti-thrombosis Effects 0.000 abstract 1
- 230000023555 blood coagulation Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 230000002441 reversible effect Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03011303A EP1479675A1 (de) | 2003-05-19 | 2003-05-19 | Indazolderivate als Faktor Xa-Inhibitoren |
| PCT/EP2004/004753 WO2004101556A1 (en) | 2003-05-19 | 2004-05-05 | INDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE429432T1 true ATE429432T1 (de) | 2009-05-15 |
Family
ID=33040950
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04731155T ATE429432T1 (de) | 2003-05-19 | 2004-05-05 | Indazolderivate als faktor xa-inhibitoren |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US7365088B2 (de) |
| EP (2) | EP1479675A1 (de) |
| JP (1) | JP4709763B2 (de) |
| AT (1) | ATE429432T1 (de) |
| AU (1) | AU2004238499A1 (de) |
| BR (1) | BRPI0410430A (de) |
| CA (1) | CA2528220A1 (de) |
| CL (1) | CL2004001080A1 (de) |
| DE (1) | DE602004020761D1 (de) |
| MX (1) | MXPA05012346A (de) |
| PE (1) | PE20050153A1 (de) |
| TW (1) | TW200510400A (de) |
| WO (1) | WO2004101556A1 (de) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003287481B2 (en) | 2002-11-08 | 2009-04-23 | Merck & Co., Inc. | Ophthalmic compositions for treating ocular hypertension |
| US7358268B2 (en) * | 2002-12-04 | 2008-04-15 | Sanofi-Aventis Deutschland Gmbh | Imidazole derivatives as factor Xa inhibitors |
| US7429581B2 (en) * | 2002-12-23 | 2008-09-30 | Sanofi-Aventis Deutschland Gmbh | Pyrazole-derivatives as factor Xa inhibitors |
| US7223780B2 (en) * | 2003-05-19 | 2007-05-29 | Sanofi-Aventis Deutschland Gmbh | Triazole-derivatives as blood clotting enzyme factor Xa inhibitors |
| US7741341B2 (en) | 2003-05-19 | 2010-06-22 | Sanofi-Aventis Deutschland Gmbh | Benzimidazole-derivatives as factor Xa inhibitors |
| US7317027B2 (en) * | 2003-05-19 | 2008-01-08 | Sanofi-Aventis Deutschland Gmbh | Azaindole-derivatives as factor Xa inhibitors |
| EP1479677A1 (de) * | 2003-05-19 | 2004-11-24 | Aventis Pharma Deutschland GmbH | Neue Indolderivate als Faktor Xa-Inhibitoren |
| CN1842335A (zh) * | 2003-09-04 | 2006-10-04 | 默克公司 | 用于治疗高眼压的眼用组合物 |
| DE10342570A1 (de) | 2003-09-15 | 2005-04-14 | Bayer Healthcare Ag | Verfahren zur Herstellung von 4-(4-Aminophenyl)-3-morpholinon |
| EP1568698A1 (de) | 2004-02-27 | 2005-08-31 | Aventis Pharma Deutschland GmbH | Pyrrolderivate als faktor-xa-inhibitoren |
| EP1571154A1 (de) * | 2004-03-03 | 2005-09-07 | Aventis Pharma Deutschland GmbH | Derivate des Beta-Alanins als Hemmer des Faktors Xa |
| EP1737471A4 (de) * | 2004-04-20 | 2010-08-25 | Rnd Pharmaceuticals | Pharmazeutische vorrichtungen und verfahren zur verwendung von lipophilen, mit silikon substituierten cyclooxygenase-2-selektiven nichtsteroidalen entzündungshemmern und derivaten |
| DE102006030479A1 (de) * | 2006-07-01 | 2008-03-20 | Merck Patent Gmbh | Indazolderivate |
| DE102006032824A1 (de) * | 2006-07-14 | 2008-01-17 | Bayer Healthcare Ag | Substituierte Indazole |
| JO2701B1 (en) | 2006-12-21 | 2013-03-03 | جلاكسو جروب ليميتد | Vehicles |
| US7985750B2 (en) | 2007-08-14 | 2011-07-26 | Concert Pharmaceuticals, Inc. | Substituted oxazolidinone derivatives |
| US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
| SG187426A1 (en) | 2008-01-04 | 2013-02-28 | Intellikine Llc | Certain chemical entities, compositions and methods |
| DE102008022221A1 (de) * | 2008-05-06 | 2009-11-12 | Universität des Saarlandes | Inhibitoren der humanen Aldosteronsynthase CYP11B2 |
| US8541404B2 (en) * | 2009-11-09 | 2013-09-24 | Elexopharm Gmbh | Inhibitors of the human aldosterone synthase CYP11B2 |
| DE102010018299A1 (de) | 2010-04-23 | 2011-10-27 | Archimica Gmbh | Verfahren zur Herstellung von 4-(4-Aminophenyl)-morpholin-3-on |
| EP3238722B1 (de) | 2011-01-10 | 2019-03-13 | Infinity Pharmaceuticals, Inc. | Festen formen von isochinolinonen |
| EP2705028B1 (de) | 2011-05-06 | 2019-08-21 | Egis Gyógyszergyár Zrt. | Verfahren zur herstellung von rivaroxaban und zwischenprodukte des verfahrens |
| US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
| EP2914296B2 (de) | 2012-11-01 | 2021-09-29 | Infinity Pharmaceuticals, Inc. | Behandlung von krebs mit pi3-kinase-isoformmodulatoren |
| WO2015160975A2 (en) | 2014-04-16 | 2015-10-22 | Infinity Pharmaceuticals, Inc. | Combination therapies |
| US11147818B2 (en) | 2016-06-24 | 2021-10-19 | Infinity Pharmaceuticals, Inc. | Combination therapies |
| CN109456205B (zh) * | 2018-12-17 | 2021-09-21 | 石河子大学 | 以取代喹啉或异喹啉酰肼吡啶-n-氧化物为配体的水相体系中的n-芳基化方法 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5506134A (en) | 1990-10-22 | 1996-04-09 | Corvas International, Inc. | Hypridoma and monoclonal antibody which inhibits blood coagulation tissue factor/factor VIIa complex |
| US5833982A (en) | 1991-02-28 | 1998-11-10 | Zymogenetics, Inc. | Modified factor VII |
| US5788965A (en) | 1991-02-28 | 1998-08-04 | Novo Nordisk A/S | Modified factor VII |
| DK0758341T3 (da) | 1994-04-26 | 2004-06-28 | Aventis Pharma Inc | Faktor Xa-inhibitorer |
| US5998424A (en) * | 1997-06-19 | 1999-12-07 | Dupont Pharmaceuticals Company | Inhibitors of factor Xa with a neutral P1 specificity group |
| US6339099B1 (en) * | 1997-06-20 | 2002-01-15 | Dupont Pharmaceuticals Company | Guanidine mimics as factor Xa inhibitors |
| EP0987274A1 (de) | 1998-09-15 | 2000-03-22 | Hoechst Marion Roussel Deutschland GmbH | Faktor VIIa Inhibitore |
| ATE280171T1 (de) * | 1998-12-23 | 2004-11-15 | Bristol Myers Squibb Pharma Co | Stickstoffhaltige heterobicyclen als faktor-xa- hemmer |
| MXPA02000888A (es) | 1999-07-28 | 2002-07-30 | Aventis Pharm Prod Inc | Compuestos de oxoazaheterociclilos substituidos. |
| DE10014645A1 (de) | 2000-03-24 | 2001-09-27 | Merck Patent Gmbh | Substituierte Biphenylderivate |
| EP1296977A1 (de) * | 2000-06-23 | 2003-04-02 | Bristol-Myers Squibb Pharma Company | Heteroaryl-phenyl-substituierte factor xa inhibitoren |
| EP1217000A1 (de) | 2000-12-23 | 2002-06-26 | Aventis Pharma Deutschland GmbH | Faktor Xa und Faktor VIIa Inhibitoren |
| IL156064A0 (en) * | 2000-12-28 | 2003-12-23 | Daiichi Seiyaku Co | Vla-4 inhibitors |
| EP1314733A1 (de) | 2001-11-22 | 2003-05-28 | Aventis Pharma Deutschland GmbH | Indol-2-carbonsäureamide als Faktor-Xa-Hemmer |
| US7358268B2 (en) | 2002-12-04 | 2008-04-15 | Sanofi-Aventis Deutschland Gmbh | Imidazole derivatives as factor Xa inhibitors |
| US7429581B2 (en) | 2002-12-23 | 2008-09-30 | Sanofi-Aventis Deutschland Gmbh | Pyrazole-derivatives as factor Xa inhibitors |
| US7317027B2 (en) | 2003-05-19 | 2008-01-08 | Sanofi-Aventis Deutschland Gmbh | Azaindole-derivatives as factor Xa inhibitors |
| EP1479677A1 (de) | 2003-05-19 | 2004-11-24 | Aventis Pharma Deutschland GmbH | Neue Indolderivate als Faktor Xa-Inhibitoren |
| US7223780B2 (en) | 2003-05-19 | 2007-05-29 | Sanofi-Aventis Deutschland Gmbh | Triazole-derivatives as blood clotting enzyme factor Xa inhibitors |
| US7741341B2 (en) | 2003-05-19 | 2010-06-22 | Sanofi-Aventis Deutschland Gmbh | Benzimidazole-derivatives as factor Xa inhibitors |
| EP1568698A1 (de) | 2004-02-27 | 2005-08-31 | Aventis Pharma Deutschland GmbH | Pyrrolderivate als faktor-xa-inhibitoren |
| EP1571154A1 (de) | 2004-03-03 | 2005-09-07 | Aventis Pharma Deutschland GmbH | Derivate des Beta-Alanins als Hemmer des Faktors Xa |
-
2003
- 2003-05-19 EP EP03011303A patent/EP1479675A1/de not_active Withdrawn
-
2004
- 2004-05-05 JP JP2006529742A patent/JP4709763B2/ja not_active Expired - Fee Related
- 2004-05-05 BR BRPI0410430-7A patent/BRPI0410430A/pt not_active IP Right Cessation
- 2004-05-05 EP EP04731155A patent/EP1628972B1/de not_active Expired - Lifetime
- 2004-05-05 WO PCT/EP2004/004753 patent/WO2004101556A1/en not_active Ceased
- 2004-05-05 CA CA002528220A patent/CA2528220A1/en not_active Abandoned
- 2004-05-05 AU AU2004238499A patent/AU2004238499A1/en not_active Abandoned
- 2004-05-05 DE DE602004020761T patent/DE602004020761D1/de not_active Expired - Lifetime
- 2004-05-05 AT AT04731155T patent/ATE429432T1/de not_active IP Right Cessation
- 2004-05-05 MX MXPA05012346A patent/MXPA05012346A/es active IP Right Grant
- 2004-05-07 PE PE2004000474A patent/PE20050153A1/es not_active Application Discontinuation
- 2004-05-17 TW TW093113796A patent/TW200510400A/zh unknown
- 2004-05-17 CL CL200401080A patent/CL2004001080A1/es unknown
- 2004-05-19 US US10/849,088 patent/US7365088B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP1479675A1 (de) | 2004-11-24 |
| CA2528220A1 (en) | 2004-11-25 |
| US20040235824A1 (en) | 2004-11-25 |
| US7365088B2 (en) | 2008-04-29 |
| DE602004020761D1 (de) | 2009-06-04 |
| PE20050153A1 (es) | 2005-04-25 |
| JP4709763B2 (ja) | 2011-06-22 |
| MXPA05012346A (es) | 2006-05-25 |
| EP1628972A1 (de) | 2006-03-01 |
| WO2004101556A1 (en) | 2004-11-25 |
| CL2004001080A1 (es) | 2005-04-08 |
| TW200510400A (en) | 2005-03-16 |
| EP1628972B1 (de) | 2009-04-22 |
| JP2006528942A (ja) | 2006-12-28 |
| AU2004238499A1 (en) | 2004-11-25 |
| BRPI0410430A (pt) | 2006-06-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE429432T1 (de) | Indazolderivate als faktor xa-inhibitoren | |
| DE602004028367D1 (de) | Neue indolderivate als faktor xa-inhibitoren | |
| NO20032820L (no) | Oksybenzamidderivater som faktor XA inhibitorer | |
| MXPA04004797A (es) | Indol-2-carboxamidas como inhibidores del factor xa. | |
| TW200505914A (en) | Pyrazole-derivatives as factor Xa inhibitors | |
| WO2005085239A3 (en) | PYRROLE-DERIVATIVES AS FACTOR Xa INHIBITORS | |
| NO20025810D0 (no) | Faktor VIIA-inhibitoriske (tio)ureaderivater, deres fremstilling og anvendelse | |
| DK1423357T3 (da) | Urinstofderivater med antiproteolytisk aktivitet | |
| ATE394396T1 (de) | Triazolderivate als faktor-xa-inhibitoren | |
| TW200504027A (en) | Imidazole-derivatives as factor Xa inhibitors | |
| TW200503696A (en) | Benzimidazole-derivatives as factor Xa inhibitors | |
| TNSN05296A1 (en) | AZAINDOLE-DERIVATIVES AS FACTOR Xa INHIBITORS | |
| TW200716620A (en) | Heteroaryl-carboxylic acid (sulfamoyl alkyl) amide-derivatives as factor Xa inhibitors | |
| JO2467B1 (en) | New indole derivatives as an inhibitor of Xa |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |